A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study

Trial Profile

A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Antineoplastics
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 01 Nov 2017 Planned End Date changed from 19 Dec 2017 to 18 Oct 2018.
    • 01 Nov 2017 Planned primary completion date changed from 19 Dec 2017 to 18 Oct 2018.
    • 23 Oct 2017 Planned End Date changed from 1 May 2024 to 19 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top